IDEAYA Biosciences (IDYA) Receivables - Other (2025 - 2026)
IDEAYA Biosciences' (IDYA) quarterly Receivables - Other came in at $6.6 million in Q1 2026, up 9.83% quarter-over-quarter from $6.0 million in Q4 2025.
IDEAYA Biosciences (IDYA) Receivables - Other (2025 - 2026) Analysis & Trends
IDEAYA Biosciences has disclosed Receivables - Other across 2 years of filings, most recently posting $6.6 million for Q1 2026.
- Receivables - Other for Q1 2026 came in at $6.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 million (changed N/A YoY), and the FY2025 annual result was $6.0 million, changed N/A from the prior year.
- Receivables - Other came in at $6.6 million for Q1 2026 at IDEAYA Biosciences, up from $6.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $6.6 million in Q1 2026 to a low of $6.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | IDEAYA Biosciences | 2.78 Bn | 2.10 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.56 Mn |
| Mar 31, 2026 | 6.56 Mn |
| Dec 31, 2025 | 5.97 Mn |
| Dec 31, 2025 | 5.97 Mn |